LHF-535 - Arenavirus 抑制劑 - 生命科學試劑 - MedChemExpress

1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemELHF-535Cat. No.: HY-112762CAS No.: 1450929-77-7分式: CHNO分量: 412.52作靶點: Arenavirus作通路: Anti-infection儲存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 month溶解性數據體外實驗 DMSO : 96.67 mg/mL (234.34 mM; Need ultrasonic)H2

2、O : 40% PEG300 5% Tween-80 45% salineSolubility: 2.42 mg/mL (5.87 mM); Clear solution2. 請依序添加每種溶劑： 10% DMSO 90% corn oilSolubility: 2.42 mg/mL (5.87 mM); Clear solution1/2 Master of Small Molecules 您邊的抑制劑師www.MedChemEBIOLOGICAL ACTIVITY物活性 LHF-535種抗病毒劑，對 Lassa，Machupo，Junin，VSVg 病毒的 EC50 分別為 1。體外研究

3、LHF-535 is a small-molecule viral entry inhibitor that targets the arenavirus envelope glycoprotein (GP). LHF-535 exhibits potent antiviral activity against a broad array of hemorrhagic fever arenaviruses. LHF-535inhibits Lassa GP-pseudotyped lentivirus with an IC50 of 0.1-0.3 nM 2.體內研究 LHF-535 (3,

4、10 or 30 mg/kg; orally; daily; 14 days) protectes mice from a lethal challenge with Tacaribe virusand dramatically reduces viral titers in plasma, spleen, and liver 2.An increase in survival is also observed when the first dose of LHF-535 (10 mg/kg) is delayed by 1, 2, or 3days after infection, demo

5、nstrating that LHF-535 is efficacious as a post-exposure therapeutic in mice 2.Animal Model: IFN-/ and- receptor-deficient AG129 mice 2Dosage: 3, 10, or 30 mg/kg/dayAdministration: Orally; daily; 14 daysResult: Effective as a post-exposure therapeutic.REFERENCES1. Dongcheng Dai, et al. Antiviral dru

6、gs for treatment of arenavirus infection. WO2013123215A2.2. Madu IG, et al. A potent Lassa virus antiviral targets an arenavirus virulence determinant. PLoS Pathog. 2018 Dec 21;14(12):e1007439.McePdfHeightCaution: Product has not been fully validated for medical applications.For research use only.Tel: 400-820